Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
FY Oncology sales grew +4%, overcoming Gx headwinds;
portfolio rejuvenation with growth drivers representing 51% of sales
Oncology net sales
USD bn, % cc
Q4
+3%
FY
+4%
15.5
3.8
3.9
14.7
+17%
+17%
1.8
2.1
Representing
6.7
7.9
54% of sales
Representing
51% of sales
2.0
1.8
--9%
Q4 2020
Q4 2021
8.0
7.6
-7%
FY 2020
FY 2021
Growth drivers¹
Mature products, Gx²
1. Include Piqray®, Adakveo®, TabrectaⓇ and Scemblix®, PromactaⓇ/Revolade®, TafinlarⓇ+ MekinistⓇ, KisqaliⓇ, LutatheraⓇ, KymriahⓇ and JakaviⓇ (marketed by Novartis ex-US). 2. Base business - other brands. Gx include Afinitor®, Exjade®/
JadenuⓇ, Glivec® and SandostatinⓇ. All % growth refers relate to cc unless otherwise stated.
33 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation